In addition, some studies have shown that GLP1R agonists can improve mortality, increased left ventricular ejection fraction, and attenuate the level of brain natriuretic peptide in the patients with type 2 diabetes and HF13–15. This evidence concerns the gene NPPB and type 2 diabetes mellitus.